Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.
Raphaèle SerorPetra MeinersGabriel BaronHendrika BootsmaSimon J BowmanClaudio VitaliJacques-Eric GottenbergElke TheanderAthanasios TzioufasSalvatore De VitaManuel Ramos-CasalsThomas DörnerLuca QuartuccioPhilippe RavaudXavier Mariettenull nullPublished in: Annals of the rheumatic diseases (2016)
ClinESSDAI appears valid and very close to the original ESSDAI. This score provides an accurate evaluation of disease activity independent of B-cell biomarkers. It could be used in various circumstances: (i) in biological/clinical studies to avoid data collinearity, (ii) in clinical trials, as secondary endpoint, to detect change independent of biological effect of the drug, (iii) in clinical practice to assess disease activity for visits where immunological tests have not been done.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- clinical trial
- juvenile idiopathic arthritis
- clinical practice
- randomized controlled trial
- emergency department
- high resolution
- electronic health record
- open label
- artificial intelligence
- deep learning
- phase iii